<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00054574</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000269889</org_study_id>
    <secondary_id>UCLA-0206074</secondary_id>
    <secondary_id>ABX-0301</secondary_id>
    <nct_id>NCT00054574</nct_id>
  </id_info>
  <brief_title>Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer</brief_title>
  <official_title>A Clinical Trial Evaluating The Safety And Efficacy Of ABX-EGF In Patients With Hormone Resistant Prostate Cancer With Elevated PSA Without Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies such as ABX-EGF can locate tumor cells and either kill them&#xD;
      or deliver tumor-killing substances to them without harming normal cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of ABX-EGF in treating patients who have&#xD;
      prostate cancer that has not responded to hormone therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the clinical effect of monoclonal antibody ABX-EGF, determined by the PSA&#xD;
           response, in patients with hormone-resistant prostate cancer with rising PSA values&#xD;
           without metastasis.&#xD;
&#xD;
        -  Determine the pharmacokinetics and safety profile (including immunogenicity) of this&#xD;
           drug in these patients.&#xD;
&#xD;
        -  Determine the overall survival of patients treated with this drug.&#xD;
&#xD;
        -  Determine the time to disease progression and time to PSA progression in patients&#xD;
           treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive monoclonal antibody ABX-EGF IV over 1 hour once weekly. Treatment continues&#xD;
      every 8 weeks for up to 6 courses in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 30-50 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">February 2004</completion_date>
  <primary_completion_date type="Actual">September 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>panitumumab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of prostate cancer with rising PSA values without metastasis&#xD;
&#xD;
               -  PSA must be at least 5 ng/mL&#xD;
&#xD;
               -  PSA must show an increase above a reference level on 2 separate occasions&#xD;
&#xD;
          -  Must have tumor over-expressing epidermal growth factor receptor (EGFr) by&#xD;
             immunohistochemistry&#xD;
&#xD;
               -  Staining must be 2+ or 3+ in at least 10% of evaluated tumor cells&#xD;
&#xD;
               -  Must have tissue available for diagnostics&#xD;
&#xD;
          -  Must have failed prior front-line luteinizing hormone-releasing hormone (LHRH)&#xD;
             analogue (e.g., leuprolide or goserelin) OR failed orchiectomy and have castrate&#xD;
             levels of testosterone (less than 50 mg/mL) NOTE: Must continue on a LHRH analogue&#xD;
             (unless an orchiectomy was performed) throughout the study&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 3 times ULN&#xD;
&#xD;
          -  AST and ALT no greater than 3 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine less then 2.2 mg/dL&#xD;
&#xD;
          -  Calcium no greater than ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Left ventricular ejection fraction at least 45% by MUGA&#xD;
&#xD;
          -  No myocardial infarction within the past year&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 1 month after study&#xD;
&#xD;
          -  No other malignancy within the past 5 years except basal cell carcinoma&#xD;
&#xD;
          -  No history of chronic medical or psychiatric condition or laboratory abnormality that&#xD;
             would preclude study participation, administration, or interpretation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 6 weeks since prior steroidal or nonsteroidal antiandrogens (4 weeks for&#xD;
             flutamide)&#xD;
&#xD;
          -  Concurrent steroid therapy allowed as replacement therapy only&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 30 days since prior investigational therapy&#xD;
&#xD;
          -  At least 30 days since prior anticancer therapy&#xD;
&#xD;
          -  No prior systemic therapy for prostate cancer (except hormonal therapy)&#xD;
&#xD;
          -  No prior anti-EGFr therapy&#xD;
&#xD;
          -  Concurrent antihypercalcemic treatment allowed in the presence of elevated calcium&#xD;
             levels but not as cancer therapy for bone disease&#xD;
&#xD;
          -  No other concurrent anti-EGFr therapy&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No other concurrent investigational therapy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arie Belldegrun, MD, FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1738</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>February 5, 2003</study_first_submitted>
  <study_first_submitted_qc>February 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2003</study_first_posted>
  <last_update_submitted>July 30, 2020</last_update_submitted>
  <last_update_submitted_qc>July 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>stage I prostate cancer</keyword>
  <keyword>stage II prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Panitumumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

